Literature DB >> 8701600

Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.

E De Clercq1.   

Abstract

(S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC, Cidofovir, Vistide) is an acyclic nucleoside phosphonate with broad-spectrum activity against a wide variety of DNA viruses including herpesviruses [Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), varicella-zoster virus (VZV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus type 6 (HHV-6) and equine and bovine herpesviruses], papovaviruses [human polyoma virus and human papilloma virus (HPV)], adeno-, irido-, hepadna-, and poxviruses. HPMPC has proved effective against these viruses in different cell culture systems and/or animal models. The mechanism of action of HPMPC is based upon the interaction of its active intracellular metabolite, the diphosphorylated HPMPC derivative HPMPCpp, with the viral DNA polymerase. HPMPCpp has been shown to block CMV DNA synthesis by DNA chain termination following incorporation of two consecutive HPMPC molecules at the 3'-end of the DNA chain. HPMPC confers a prolonged antiviral action, which lasts for several days or weeks, thus allowing infrequent dosing (i.e. every week or every two weeks). This prolonged antiviral action is probably due to the very long intracellular half-life of the HPMPC metabolites, particularly the HPMPCp-choline adduct. In clinical studies, HPMPC has proved efficacious in the treatment of CMV retinitis, following both intravenous injection (3 or 5 mg/kg, every other week) and intravitreal injection (single dose of 20 micrograms per eye). Initial clinical trials also point to the efficacy of both systemic (intravenous) and topical HPMPC (1% ointment) in the treatment of acyclovir-resistant HSV infections, and of topical HPMPC (ointment or injection) in the treatment of pharyngeal, laryngeal and anogenital HPV infections. HPMPC is now being pursued in the topical and/or systemic (intravenous) treatment of various infections due to CMV, HSV, VZV, EBV, HPV, polyoma-, adeno- and poxviruses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8701600

Source DB:  PubMed          Journal:  Verh K Acad Geneeskd Belg        ISSN: 0302-6469


  14 in total

1.  Successful treatment of squamous cell carcinoma of the lower eyelid with intralesional cidofovir.

Authors:  D Calista; L Riccioni; L Coccia
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

2.  Cidofovir: a novel antitumor agent for glioblastoma.

Authors:  Piotr Hadaczek; Tomoko Ozawa; Liliana Soroceanu; Yasuyuki Yoshida; Lisa Matlaf; Eric Singer; Estefania Fiallos; C David James; Charles S Cobbs
Journal:  Clin Cancer Res       Date:  2013-10-29       Impact factor: 12.531

Review 3.  Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

4.  Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.

Authors:  Mark N Prichard; Caroll B Hartline; Emma A Harden; Shannon L Daily; James R Beadle; Nadejda Valiaeva; Earl R Kern; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

5.  Treatment of Resıstant Cyclophosphamide Induced Haemorrhagic Cystıtıs: Revıew of Literature and Three Case Reports.

Authors:  Turgay Ebiloglu; Engin Kaya; Sercan Yilmaz; Gökhan Özgür; Yusuf Kibar
Journal:  J Clin Diagn Res       Date:  2016-04-01

Review 6.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

7.  Comparative whole genome sequence analysis of wild-type and cidofovir-resistant monkeypoxvirus.

Authors:  Jason Farlow; Mohamed Ait Ichou; John Huggins; Sofi Ibrahim
Journal:  Virol J       Date:  2010-05-28       Impact factor: 4.099

8.  Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.

Authors:  Scott Parker; Jill Schriewer; Christina Oberle; Alice Robertson; Randall Lanier; George Painter; R Mark Buller
Journal:  Antivir Ther       Date:  2008

9.  Evolution of an amino acid based prodrug approach: stay tuned.

Authors:  Ivan S Krylov; Boris A Kashemirov; John M Hilfinger; Charles E McKenna
Journal:  Mol Pharm       Date:  2013-01-22       Impact factor: 4.939

10.  Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs.

Authors:  Don B Gammon; Robert Snoeck; Pierre Fiten; Marcela Krecmerová; Antonín Holý; Erik De Clercq; Ghislain Opdenakker; David H Evans; Graciela Andrei
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.